Kamal Chemali, MD
Neurology · Norfolk, VANPI 1265474795
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,050 of the $14,263 with a category attached, or 77.5%. CSL Behring accounts for 84.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $7,964 and has fallen 72.9% since, to $2,160 in 2025.
Across 57 payments — averaging $250.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$12K
- Argenx US, Inc.$673
- UCB, Inc.$594
- Catalyst Pharmaceuticals, Inc.$236
- Alnylam Pharmaceuticals Inc.$226
- AbbVie$125
- plus $372 from 8 others
Across 294 payments — averaging $2348.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$500K
- CSL Behring$189K
- Lundbeck LLC$1K
What the payments were for
- Consulting fees$11,05077%
- Travel & lodging$1,1918%
- Food & beverage$2,02214%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 17 | $12,038 |
| Argenx US, Inc. | 10 | $673 |
| UCB, Inc. | 9 | $594 |
| Catalyst Pharmaceuticals, Inc. | 3 | $236 |
| Alnylam Pharmaceuticals Inc. | 6 | $226 |
| AbbVie | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $105 |
| Impel Pharmaceuticals Inc. | 1 | $97 |
| AstraZeneca(2 entities) | 3 | $67 |
| Lilly USA, LLC | 2 | $32 |
| TG Therapeutics, Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $18 |
| Amgen | 1 | $16 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,263 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $137,753 |
| Propranolol Hcl | 19 | $199 |
| Gabapentin | 11 | $190 |
Paid to pharmacies, not to this prescriber.
Other neurology in Norfolk
- Ingrid Loma MillerNorfolk$364K
- Carmen FuentesNorfolk$339K
- Tara KimbasonNorfolk$119K
- Alice EdwardsNorfolk$111K
- Firas BeitinjanehNorfolk$31K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.